Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
Key takeaways
- TREMFYA maintains or improves fistula remission through 48 weeks, with the 100 mg dose showing a 7‑point lift from Week 24 to Week 48.
- 48‑week combined fistula remission 35% (100 mg dose)
- 28% remission at Week 24 (100 mg dose)
What happened
Johnson & Johnson’s drug TREMFYA (guselkumab) kept or improved fistula remission in adults with Crohn’s disease through 48 weeks in the Phase 3 FUZION study, with the 100 mg dose group rising from 28 % remission at Week 24 to 35 % at Week 48.
Why it matters
Fistulas are a tough complication of Crohn’s disease; showing sustained remission supports TREMFYA’s role in treating this hard‑to‑treat condition and may broaden its use in the Crohn’s market.
Short-term and longer-term
Short-term. Over the next few days the stock may react to the 48‑week data release and the UEG presentation.
Longer-term. For investors, the sustained efficacy could enhance TREMFYA’s long‑term commercial prospects in the Crohn’s disease segment, potentially affecting the company’s revenue outlook over the next few quarters.